University of Kansas

University of Michigan

Hylapharm, LLC

Laird Forrest

Ti Zhang

Jordan Hunt

Shuang Cai

Mark S Cohen

Daniel J Aires

Qiuhong Yang

Steven R Buchman

Alexis Donneys

Russell Swerdlow

Eli Michaelis

Peter Kleindl

Ryan Moulder

Heather Wilkins

Noah Nelson

Ruolin Lu

Chad E Groer

Chad Groer

The present invention relates to novel therapeutic nanoparticles. In particular, the present invention is directed to nanoparticles associated (e.g., complexed, conjugated, encapsulated, absorbed, adsorbed, admixed) with angiogenesis-activating-agents, methods of synthesizing the same, devices or compositions comprising such nanoparticles, as well as systems and methods utilizing the nanoparticles (e.g., in therapeutic settings for enhancing and/or activating angiogenesis at targeted tissue region).

Devices, compositions and related methods for accelerating and enhancing bone repair

The present technology is directed to TLR7 and TLR8 agonist compounds, compositions, and methods of using the same for the treatment of cancers and as vaccine adjuvants.

Imidazoquinoline compounds and prodrugs thereof

Compounds, compositions, and methods related to bioenergetic metabolism are provided. The compounds and compositions are suited to promote bioenergetic processes including cellular respiration and glycolytic flux and may be used to treat mitochondrial disorders, neurodegenerative diseases (such as Alzheimer's disease (AD), Parkinson's disease, and/or amyotrophic lateral sclerosis), multiple sclerosis, and/or epilepsy.

Bioenergetically active esters for health and disease

Provided are platinum(IV) compounds of Formula I or pharmaceutically acceptable salts thereof. Also provided are compositions including such compounds as well as methods of using the same.

Platinum(IV) conjugates and methods of use

Compounds, compositions, and methods related to bioenergetic metabolism are provided. The compounds and com positions are suited to promote bioenergetic processes including cellular respiration and glycolytic flux and may be used to treat mitochondrial disorders, neurodegenerative diseases (such as Alzheimer's disease (AD), Parkinson's disease, and/or amyotrophic lateral sclerosis), multiple sclerosis, and/or epilepsy.

A chemotherapeutic composition can be configured for subcutaneous administration for preferential intralymphatic accumulation while also providing a therapeutic systemic concentration that is not toxic. The composition can include a pharmaceutically acceptable carrier, and a nanoconjugate configured for preferential intralymphatic accumulation after subcutaneous administration. The nanoconjugate can include a nanocarrier configured for preferential intralymphatic accumulation after subcutaneous or interstitial administration, and a plurality of chemotherapeutic agents coupled to the nanocarrier. The nanoconjugate can have a dimension of about 10 nm to about 50 nm. Also, the nanoconjugate can be loaded with the chemotherapeutic agents from about 10% to about 50% w/w. The nanocarrier can be a hyaluronan polymer of about 3 kDa to about 50 kDa. Alternatively, the nanocarrier can be a dendrimer.

Intralymphatic chemotherapy drug carriers

Growing community of inventors

Lawrence, KS, United States of America

Laird Forrest